Sexual Function and the Icariin PDE5 Question

Most herbal sex claims are built on nothing much: a folk name, a testimonial, a rat study with twelve animals. The Epimedium claim is not like that. It rests on something genuinely real — icariin inhibits phosphodiesterase-5, the exact enzyme that sildenafil blocks. That has been measured, replicated, and published in serious journals by serious laboratories.

Which makes this page harder to write, and more worth reading. It is easy to dismiss a claim with no mechanism. It is much harder, and much more useful, to explain why a claim with a correct mechanism still does not work. That gap — between inhibiting an enzyme in a dish and helping a man in a bedroom — is the whole subject here, and Epimedium happens to be the clearest worked example of it in the entire supplement aisle.

Table of Contents

1. Why This Claim Is Different
2. How an Erection Actually Works
3. What Icariin Really Does to PDE5
4. The Three Gaps Between Dish and Person
5. The Metabolite Counter-Argument
6. The Animal Studies, Fairly Described
7. The Trial Nobody Has Run
8. Erectile Dysfunction Is a Heart Warning
9. If You Are Going to Try It Anyway
10. Cautions and Interactions
11. Key Research Papers
12. Connections

Why This Claim Is Different

In 2008 a group at the University of Milan did something admirably direct. They took four plant extracts with long reputations for treating male impotence — Tribulus terrestris, Ferula hermonis, Epimedium brevicornum and Cinnamomum cassia — plus three isolated compounds, and screened all of them against purified human PDE5.

Almost everything failed. Cinnamaldehyde: nothing. Ferutinin: nothing. Tribulus, the ingredient stacked into half the testosterone-boosting products on the market: nothing. Only one extract and one compound showed real activity, and they were the same plant — Epimedium brevicornum, and its flavonoid icariin.

So the reputation is not arbitrary. Out of a lineup of traditional aphrodisiacs, this is the one that actually hits the target. That is a genuine scientific finding and it deserves to be stated plainly before anything is taken away from it.

How an Erection Actually Works

The plumbing is worth understanding, because it explains both why PDE5 matters and why a weak PDE5 inhibitor is not simply a mild version of a strong one.

Sexual arousal causes nerve endings and the endothelium lining the penile arteries to release nitric oxide. Nitric oxide switches on an enzyme called guanylate cyclase, which manufactures a messenger molecule, cyclic GMP (cGMP). Cyclic GMP tells the smooth muscle wrapped around the arteries and the spongy erectile tissue to relax. Relaxed muscle means the arteries open, blood floods in, the tissue swells, and the swelling compresses the veins that would otherwise drain it. That is an erection: a hydraulic event driven by a chemical signal.

The signal has to end, so the body includes an off-switch: phosphodiesterase-5, an enzyme concentrated in penile tissue whose job is to chew up cGMP. When cGMP falls, the muscle re-tightens, blood drains, and the erection subsides.

Sildenafil, tadalafil and vardenafil work by blocking the off-switch. They do not create arousal and they do not create nitric oxide. They simply stop cGMP being destroyed, so whatever signal arousal produces lasts longer and builds higher. This is why PDE5 drugs do nothing without sexual stimulation, and it is also why they are so precisely dose-dependent: the whole effect is a tug-of-war between how fast cGMP is made and how fast it is destroyed. Slow the destruction a little and you change nothing perceptible. Slow it a lot and you change everything.

What Icariin Really Does to PDE5

The standard measure of an inhibitor is the IC₅₀: the concentration that blocks half the enzyme’s activity. Lower is stronger. Here are the published figures.

Two things fall out of that table, and both matter.

First: the impressive numbers belong to a molecule that is not in the bottle. When you read that an icariin compound matched sildenafil almost exactly — 75 nM against 74 nM — that is true, and it is a real achievement of medicinal chemistry. But the compound is 3,7-bis(2-hydroxyethyl)icaritin, a semi-synthetic derivative built by chemically stripping both sugars off icariin and bolting on hydroxyethyl groups. It is 80 times more potent than natural icariin precisely because it is not natural icariin. Marketing copy that cites this study for horny goat weed capsules is quoting the sentence about the drug candidate and omitting the sentence about the herb.

Second: even icariin’s best showing puts it in the company of a failed drug. Zaprinast reached PDE5 at a few hundred nanomolar and was abandoned as a clinical dead end — too weak, too unselective. Icariin is roughly three times weaker than that. It is not a mild PDE5 inhibitor; it is below the floor at which PDE5 inhibition was ever clinically useful.

The Three Gaps Between Dish and Person

Gap one: potency

Covered above. Depending on which assay you take, icariin is somewhere between 3 and 80 times weaker than compounds that are themselves either marginal or, in sildenafil’s case, dosed at 25–100 mg of pure drug. Weakness alone might be survivable if you could simply take more — which brings us to the second gap.

Gap two: absorption

You cannot simply take more, because icariin barely gets in. Its two attached sugars make it bulky and hydrophilic, and the intestinal wall does not transport it well. What happens instead is that gut bacteria and intestinal enzymes take the sugars off, in sequence: icariin becomes icariside I, then icariside II, then icaritin, and finally desmethylicaritin. Each step makes the molecule smaller, less water-soluble and more absorbable — and each step also makes it a different molecule from the one whose IC₅₀ was measured.

This was measured directly in people. In a randomised, double-blind, placebo-controlled trial at the National University of Singapore, 58 postmenopausal women took either 740 mg per day of a purified Epimedium prenylflavonoid extract or placebo for six weeks, with serum sampled and analysed by tandem mass spectrometry. The result was unambiguous:

• Icariin: below the limit of detection. Not low — absent.
• Icariside I: also below detection.
• Detected in serum: desmethylicaritin, icaritin and icariside II.
• Median peak concentration of desmethylicaritin, the dominant circulating species: 60.9 nM.

Set that against the enzyme numbers. Icariin needs 1,000–5,900 nM to half-inhibit PDE5. After a substantial daily dose of a purified extract — far more concentrated than a typical shelf capsule — icariin is not measurable in blood at all, and the metabolite that is present peaks at about one-sixteenth to one-hundredth of that threshold. The concentration required for the mechanism and the concentration achieved in a human differ by one to two orders of magnitude, in the wrong direction.

Gap three: nobody has run the trial

The third gap is the simplest and the most damning. Sildenafil was approved in 1998. Icariin’s PDE5 activity was published in 2006 and 2008. In the two decades since, with a global market for “natural” erectile remedies worth billions, no adequate randomised, placebo-controlled trial of Epimedium or icariin for erectile dysfunction in men has been published.

This is not a case of evidence that exists but is weak. It is an absence. Erectile dysfunction is one of the easiest conditions in medicine to study: there is a validated, self-administered questionnaire (the International Index of Erectile Function, and its five-item short form the IIEF-5), the effect sizes of working drugs are large, and volunteers are easy to recruit. A competent 12-week trial in 150 men would settle the question and would not be expensive. It has not been done, and the most recent review of icariin’s mechanisms in erectile dysfunction — published in Sexual Medicine Reviews in 2026 by a urology department that is broadly sympathetic to the compound — ends with the same conclusion: clinical efficacy “still requires further confirmation in high-quality randomized controlled trials.”

When a claim is easy to test, commercially valuable, and remains untested after twenty years, that is itself information.

The Metabolite Counter-Argument

There is a serious response to everything above, and it deserves a fair hearing rather than a dismissal.

The argument goes: you are measuring the wrong molecule. Icariin is a pro-drug — a delivery vehicle, not the active agent. The compound that matters in the body is icariside II, and possibly icaritin. Icariside II is smaller, better absorbed, and in several reports more potent than icariin. The 2026 review states plainly that “the principal bioactive form of icariside in vivo is icariside II.” And icariside II was detected in the serum of the Singapore trial participants. So testing icariin against an enzyme and then measuring icariin in blood may simply be the wrong experiment twice over.

That argument is coherent, and it is where the field’s own researchers are working. Structural biology groups are still actively mapping how Epimedium constituents dock into PDE5A, and pharmacokinetic groups are comparing formulations specifically designed to raise icariside II exposure. This is live science, not a dead end.

But notice what it does and does not establish. It gives a reason why the herb might work despite the icariin numbers. It does not supply a measured icariside II blood concentration in humans that reaches a PDE5-inhibiting range, and it does not supply a clinical outcome. It moves the claim from “refuted by pharmacokinetics” to “unresolved and untested” — which is a real improvement, and still not a reason to buy anything. A hypothesis about a metabolite is not a treatment.

The Animal Studies, Fairly Described

The animal literature is where the herb looks best, and it is worth describing accurately because it is genuinely interesting work.

• Nerve-injury models. Rats whose cavernous nerves have been crushed — a laboratory analogue of the nerve damage caused by radical prostatectomy — showed better erectile responses and evidence of nerve regeneration after icariin. This is a neurotrophic effect, not a PDE5 effect, and it is arguably the more novel finding.
• Diabetes models. In type 1 diabetic rats, icariin reduced cell death in penile cavernous tissue and improved erectile function. A separate line of work found icariside II improved erectile responses in diabetic rats with changes in advanced glycation end-products, autophagy, mTOR signalling and the nitric oxide–cGMP pathway.
• Hypertension models. In spontaneously hypertensive rats, icariin improved erectile function, apparently by downregulating a signalling kinase called GRK2 in cavernous tissue.
• Combination approaches. Icariin has been tested alongside mesenchymal stem cell injection for diabetes-associated erectile dysfunction, again in rats.

Three honest observations about this body of work. It is consistent — different labs, different disease models, broadly the same direction. It is mechanistically diverse, which cuts both ways: nitric oxide signalling, RhoA/ROCK inhibition, reduced autophagy, testosterone synthesis, stem-cell markers and PDE5 inhibition have all been proposed, and a compound credited with eight mechanisms is often a compound whose real mechanism is not yet known. And it is almost entirely injected or high-dose, bypassing the absorption problem that defines the human situation.

Rats are also, bluntly, a poor guide here. Rodent erectile models measure intracavernosal pressure under electrical nerve stimulation in an anaesthetised animal. They are a reasonable screen and a terrible predictor. Many compounds that pass them have failed in men.

The Trial Nobody Has Run

It is worth being concrete about what would actually change the verdict on this page, because “more research is needed” is a phrase that hides more than it reveals.

An adequate trial would look like this: 150–300 men with mild to moderate erectile dysfunction, randomised double-blind to a defined Epimedium preparation or matching placebo, 12 weeks, primary outcome the change in IIEF-5 score, with the Sexual Encounter Profile questions on penetration and completion as secondary outcomes. The product would be characterised by mass spectrometry before dosing and screened for PDE5-inhibitor adulterants. Blood levels of icariin, icariside II, icaritin and desmethylicaritin would be measured, so that a positive result could be tied to an exposure and a negative result could be shown not to be a dosing failure.

None of that is exotic. It is a standard urology trial design that has been run dozens of times for other agents. Until something like it exists, anyone selling this herb for erectile dysfunction is selling an enzyme assay.

Erectile Dysfunction Is a Heart Warning

This is the most useful paragraph on this page, and it has nothing to do with the herb.

Erectile dysfunction is frequently the first symptom of cardiovascular disease. The reason is anatomical. Erections depend on the endothelium — the single-cell lining of blood vessels — releasing nitric oxide on demand. Endothelial dysfunction is the earliest stage of atherosclerosis, and it shows up in small arteries before large ones. The penile arteries are roughly 1–2 mm across; the coronary arteries are 3–4 mm. The same plaque burden that produces no cardiac symptom at all can measurably impair a vessel a third the size. Erectile dysfunction is, in effect, a stress test you did not schedule.

The epidemiology backs this up hard. In the Prostate Cancer Prevention Trial, more than 9,000 men were followed for years; incident erectile dysfunction was associated with a significantly increased risk of subsequent cardiovascular events, and the authors described its predictive value as comparable to conventional risk factors such as smoking or a family history of myocardial infarction. A later meta-analysis pooling cohort studies found erectile dysfunction predicted cardiovascular events, cardiovascular mortality and all-cause mortality, independent of the usual risk factors. Subsequent analyses have continued to confirm it, including imaging work showing higher coronary calcium scores in men presenting with erectile dysfunction.

The clinically important detail is the lead time: erectile symptoms typically precede a cardiac event by a period measured in years, not weeks. That is a window in which blood pressure, lipids, glucose and smoking can all be addressed.

So here is the practical version. If you have developed erectile dysfunction, the highest-value action available to you is not choosing a supplement. It is a doctor’s appointment that produces a blood pressure reading, a fasting lipid panel, an HbA1c, a testosterone level if indicated, and an honest conversation about smoking, alcohol, weight, sleep apnoea and the medications you already take. Common culprits hide in plain sight: thiazide diuretics, beta-blockers, SSRIs and finasteride all cause erectile dysfunction routinely, and all are adjustable. Buying horny goat weed instead of making that appointment is the one genuinely dangerous thing you can do with this herb — not because the herb hurts you, but because it delays a diagnosis you would want early.

If You Are Going to Try It Anyway

People are going to try it. That is a reasonable thing to do with a cheap, low-risk-looking botanical, and pretending otherwise helps nobody. So, practically:

1. Rule out the cardiovascular question first. See the section above. This is not a formality.
2. Buy a product that names a species and an icariin percentage. If it says only “horny goat weed extract 500 mg,” you have no idea what you bought.
3. Avoid every “proprietary blend” and every product promising fast results. This is the adulteration filter, and it is the most important step. See Safety, Adulteration and Product Quality.
4. Never combine it with a prescription PDE5 inhibitor or with any nitrate. Not because icariin is strong, but because you cannot be certain what is in the capsule.
5. Give it a defined trial and then stop. Six to eight weeks. If nothing has changed, nothing is going to; continuing is money spent on hope.
6. Tell your doctor and your pharmacist. Especially if you take anything for blood pressure, heart rhythm, or blood clotting.

What the evidence actually supports instead

For erectile dysfunction specifically, the interventions with real trial support are unglamorous: treating the underlying vascular and metabolic disease, stopping smoking, losing weight if relevant, treating obstructive sleep apnoea, reviewing culprit medications, addressing depression and relationship factors, pelvic floor exercise, and — where appropriate and prescribed — an actual PDE5 inhibitor, which is inexpensive as a generic, extremely well characterised, and safe under medical supervision in men without nitrate use.

Cautions and Interactions

• Nitrates — absolute avoidance. Nitroglycerin, isosorbide mononitrate or dinitrate, amyl nitrite and recreational “poppers.” Combining a nitrate with any PDE5 inhibitor causes severe, potentially fatal hypotension. The herb itself is a weak inhibitor, but adulterated products are not, and you cannot tell them apart by looking.
• Prescription PDE5 inhibitors. Do not stack sildenafil, tadalafil, vardenafil or avanafil with this herb.
• Blood-pressure medication, including alpha-blockers. Additive hypotension is plausible and, with a spiked product, likely. Alpha-blockers such as tamsulosin are a particular concern.
• Anticoagulants and antiplatelets. Warfarin, apixaban, rivaroxaban, clopidogrel, aspirin. Interaction data for Epimedium are thin, and thin data on an anticoagulant is a reason for caution, not reassurance. Discuss with a pharmacist before starting.
• Heart rhythm. A published case report describes tachyarrhythmia together with a hypomanic mood change in a man taking horny goat weed. One case does not prove causation, but combined with the herb’s vascular activity it is a reasonable reason for anyone with an arrhythmia or structural heart disease to avoid it.
• Hormone-sensitive conditions. Epimedium flavonoids activate oestrogen receptor alpha. Avoid in oestrogen-receptor-positive breast cancer, endometrial or ovarian cancer, endometriosis and uterine fibroids unless a specialist advises otherwise.
• Liver. Liver injury is the most frequently reported adverse effect of Epimedium in the Chinese pharmacovigilance literature. Avoid with existing liver disease; stop and seek care for dark urine, pale stools, right-upper-quadrant pain or yellowing of the eyes.
• Pregnancy and breastfeeding — avoid. No safety data, and demonstrable hormonal activity.
• Surgery. Stop at least two weeks beforehand because of the blood-pressure and bleeding uncertainties.

Back to Table of Contents

Key Research Papers

Each identifier below was verified live against NCBI E-utilities — first author, title, journal and year all had to match.

The PDE5 measurements

1. Dell’Agli M, Galli GV, Dal Cero E, Belluti F, Matera R, Zironi E, Pagliuca G, Bosisio E. Potent inhibition of human phosphodiesterase-5 by icariin derivatives. Journal of Natural Products. 2008;71(9):1513–1517. Icariin IC₅₀ 5.9 µM versus sildenafil 74 nM; Tribulus and Cinnamomum inactive.
2. Ning H, Xin ZC, Lin G, Banie L, Lue TF, Lin CS. Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology. 2006;68(6):1350–1354. Icariin IC₅₀ 0.75–1.1 µM, about three times weaker than zaprinast.
3. Chau Y, et al. Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5. PLoS One. 2019;14(9):e0222803.
4. Fang Y, et al. Mechanistic study of PDE5A inhibitors from the prepared folium of Epimedium sagittatum Maxim. Journal of Structural Biology. 2026;218(1):108279.
5. Lan TH, et al. 3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP signalling. European Journal of Pharmacology. 2018;829:102–111. The synthetic derivative, pursued as a drug candidate rather than a supplement.

What reaches human blood

1. Yong EL, Cheong WF, Huang Z, Thu WPP, Cazenave-Gassiot A, Seng KY, Logan S. Randomized, double-blind, placebo-controlled trial to examine the safety, pharmacokinetics and effects of Epimedium prenylflavonoids, on bone specific alkaline phosphatase and the osteoclast adaptor protein TRAF6 in post-menopausal women. Phytomedicine. 2021;91:153680. Icariin below detection after 740 mg/day; desmethylicaritin C_max 60.9 nM.
2. Li C, Li Q, Mei Q, Lu T. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sciences. 2015;126:57–68.
3. Ding Z, Chen X, Tang D, et al. Comparisons of the bioavailability of icariin, icariside II, and epimedin C in rats after oral administration of total flavonoids of Epimedium brevicornu Maxim. and its three formulations. Journal of Pharmaceutical and Biomedical Analysis. 2025;255:116631.

Animal and mechanistic work in erectile dysfunction

1. Meng C, Jiang R. Molecular mechanisms of icariin in the treatment of erectile dysfunction. Sexual Medicine Reviews. 2026;14(3):qeag051. The current synthesis, and the source of the “icariside II is the principal bioactive form in vivo” position.
2. Shindel AW, Xin ZC, Lin G, et al. Erectogenic and neurotrophic effects of icariin, a purified extract of horny goat weed (Epimedium spp.) in vitro and in vivo. The Journal of Sexual Medicine. 2010;7(4 Pt 1):1518–1528.
3. Zhang J, et al. Effect of icarisid II on diabetic rats with erectile dysfunction and its potential mechanism via assessment of AGEs, autophagy, mTOR and the NO–cGMP pathway. Asian Journal of Andrology. 2013;15(1):143–148.
4. Yang H, et al. Icariin inhibits hyperglycemia-induced cell death in penile cavernous tissue and improves erectile function in type 1 diabetic rats. Sexual Medicine. 2025;13(1):qfaf017.
5. Li Y, et al. Icariin improves erectile function in spontaneously hypertensive rats by downregulating GRK2 in penile cavernous tissue. The Journal of Sexual Medicine. 2025;22(3):387–396.
6. Wang X, et al. Combination of mesenchymal stem cell injection with icariin for the treatment of diabetes-associated erectile dysfunction. PLoS One. 2017;12(3):e0174145.

Erectile dysfunction as a cardiovascular predictor

1. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294(23):2996–3002.
2. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circulation: Cardiovascular Quality and Outcomes. 2013;6(1):99–109.
3. Zhao B, et al. Erectile dysfunction predicts cardiovascular events as an independent risk factor: a systematic review and meta-analysis. The Journal of Sexual Medicine. 2019;16(7):1005–1017.
4. An J, et al. Understanding the erectile dysfunction–cardiovascular disease connection: clinical and pathophysiological insights. Sexual Medicine Reviews. 2025;13(3):406–422.
5. Ziadeh H, et al. Erectile dysfunction as a predictor of subclinical atherosclerosis: a community health assessment using coronary calcium scoring. Urology. 2026;209:144–148.

Safety

1. Partin JF, Pushkin YR. Tachyarrhythmia and hypomania with horny goat weed. Psychosomatics. 2004;45(6):536–537.
2. Balayssac S, Danoun S, Gilard V, Martino R, Malet-Martino M. The POWER saga from 2007 to 2022: an example of a sexual enhancement dietary supplement tainted by different adulterants and still on the market. Journal of Pharmaceutical and Biomedical Analysis. 2023;227:115283.

Live PubMed Searches

1. Epimedium and erectile dysfunction
2. Icariin and PDE5
3. Icariside II and erectile function
4. Icariin clinical trials
5. Erectile dysfunction and endothelial dysfunction
6. IIEF-5 outcome measure
7. PDE5 inhibitors and nitrate hypotension
8. Herbal aphrodisiacs in randomised trials

Connections

• All Herbs
• Epimedium Benefits — hub
• Epimedium (Horny Goat Weed)
• Safety, Adulteration and Product Quality
• Bone Density and Menopause
• Tongkat Ali
• Maca
• Tribulus — screened for PDE5 activity and found inactive
• Cardiology

Back to Table of Contents